RHYTHM PHARMACEUTICALS INC's ticker is RYTM and the CUSIP is 76243J105. A total of 147 filers reported holding RHYTHM PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 0.18 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $238,306 | +39.5% | 10,395 | +0.3% | 0.00% | – |
| Q2 2023 | $170,854 | +10.2% | 10,361 | -23.1% | 0.00% | – |
| Q1 2022 | $155,000 | -7.7% | 13,465 | -19.4% | 0.00% | – |
| Q4 2021 | $168,000 | -21.5% | 16,707 | +2.0% | 0.00% | -100.0% |
| Q3 2021 | $214,000 | -46.5% | 16,375 | -19.9% | 0.00% | 0.0% |
| Q2 2021 | $400,000 | +10.5% | 20,450 | +20.3% | 0.00% | 0.0% |
| Q1 2021 | $362,000 | -14.6% | 16,996 | +19.1% | 0.00% | -50.0% |
| Q4 2020 | $424,000 | +74.5% | 14,269 | +27.1% | 0.00% | +100.0% |
| Q3 2020 | $243,000 | -6.2% | 11,229 | -3.3% | 0.00% | 0.0% |
| Q2 2020 | $259,000 | -16.2% | 11,612 | -13.8% | 0.00% | 0.0% |
| Q4 2019 | $309,000 | +19.8% | 13,472 | +12.7% | 0.00% | 0.0% |
| Q3 2019 | $258,000 | +0.4% | 11,958 | +2.5% | 0.00% | -50.0% |
| Q2 2019 | $257,000 | -29.8% | 11,661 | -12.6% | 0.00% | 0.0% |
| Q1 2019 | $366,000 | +2.5% | 13,343 | +0.6% | 0.00% | 0.0% |
| Q4 2018 | $357,000 | – | 13,266 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| NEA Management Company, LLC | 4,909,956 | $142,977,919 | 8.04% |
| Opaleye Management Inc. | 735,000 | $21,403,200 | 7.44% |
| Frazier Life Sciences Management, L.P. | 1,894,000 | $55,153,280 | 3.43% |
| RA Capital Management | 5,516,067 | $160,627,871 | 3.26% |
| Altium Capital Management LP | 170,000 | $4,950,400 | 2.52% |
| Samsara BioCapital, LLC | 345,293 | $10,054,932 | 2.16% |
| Rock Springs Capital Management LP | 1,760,865 | $51,276,389 | 1.23% |
| Parkman Healthcare Partners LLC | 157,862 | $4,596,941 | 1.22% |
| Baker Brothers Advisors | 6,354,608 | $185,046,185 | 1.11% |
| EAM Investors, LLC | 164,695 | $4,795,918 | 0.99% |